In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions-Reference-Cited by-同舟云学术

In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions

Published:2018-08-09 Issue:6 Volume:123 Page:739-748
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Filppula Anne M.¹,Mustonen Tiffany M.¹,Backman Janne T.¹

Affiliation:

1. Department of Clinical Pharmacology; University of Helsinki and Helsinki University Hospital; Helsinki Finland

Funder

National Fund for University Level Health Research, Finland

Academy of Finland

Orion-Farmos Research Foundation

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcpt.13088/fullpdf

Reference68 articles.

1. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors;Shao;J Pharm Sci,2014

2. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates;Filppula;Br J Pharmacol,2012

3. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors;Filppula;Drug Metab Dispos,2014

4. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction;Kenny;Pharm Res,2012

5. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials;Wang;Drug Metab Dispos,2014

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08

2. Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities;Drug Metabolism and Disposition;2024-01-29

3. Preclinical evaluation of chemically reactive metabolites and mitigation of bioactivation in drug discovery;Drug Discovery Today;2023-07

4. The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases;Precision Medical Sciences;2023-05-29

5. Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape;Expert Review of Clinical Pharmacology;2023-02-01